Medical/Pharmaceuticals
Sanyou Biopharmaceuticals completes series B financing and secures its leading role in innovative antibody drug discovery
SHANGHAI, June 26, 2021 /PRNewswire/ -- Sanyou Biopharmaceutical (Shanghai) Co., Ltd. (hereafter referred to as "Sanyou Bio" or "the Company"), a leading company in innovative antibody drug discovery, announced the closing of series B financing. This financing round was co-led by LH Ventures and ...
2021-06-26 23:00
4355
World-first predictive test for Diabetic Kidney Disease could save $384 billion over 10 years
* Independent modelling estimates the PromarkerD predictive test for diabetic kidney disease (DKD) would increase the quality of care and could save US payers almostUSD400 billion over 10 years * The US is home to 31 million adults with diabetes who are at risk of DKD - cost savings stem from...
2021-06-25 23:30
3216
China's Public Health System Primed for Digital Innovation Online/Offline Service Delivery 'Huge Growth Opportunity', says Ping An Co-CEO
HONG KONG and SHANGHAI, June 25, 2021 /PRNewswire/ -- Ping An is investing further in its healthcare ecosystem to meet the growing public healthcare needs inChina, says Jessica Tan, Co-CEO of Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318; SSE: 60...
2021-06-25 21:19
28324
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus
SHANGHAI and GAITHERSBURG, Md., June 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China N...
2021-06-25 20:00
16819
InnoCare Announces Approval of Initiation of Phase 1 Clinical Trial of RTK Inhibitor ICP-033 in China
BEIJING, June 25, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today thatChina's National Medical Products Administration (NMPA) has approved the initiation of a Phase I clinical trial of ICP-033, the Compan...
2021-06-25 19:04
16759
HistoIndex's AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in Nonalcoholic Steatohepatitis (NASH) Patients Treated with Tropifexor Compared with Placebo
SINGAPORE, June 25, 2021 /PRNewswire/ -- HistoIndex
2021-06-25 18:30
2653
Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003
HANGZHOU, China, June 25, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), an innovative drug development company, announced today that its new Class I innovative drug LNK01003, has been approved by National Medical Products Administration (...
2021-06-25 15:11
5545
Research showed that InxMed FAK Inhibitor (IN10018) Overcomes Drug Resistance of KRAS G12C inhibitors and Synergizes with KRAS G12C inhibitors in Treating Cancer
SHANGHAI, June 25, 2021 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today one study in collaboration with Ruijin Hospital, Shanghai Jiaotong ...
2021-06-25 15:06
1936
Zuellig Pharma Selects CYFIRMA to Elevate Cyber-intelligence Capabilities and Strengthen Cybersecurity Posture
SINGAPORE, June 25, 2021 /PRNewswire/ -- CYFIRMA, a threat discovery and
cyber-intelligence platform company, funded by Goldman Sachs, Zodius Capital
and Z3Partners, today announced thatZuellig Pharma
2021-06-25 12:57
2699
GenScript receives "Best Contract Development and Manufacturing Organization Award" in the Korea Bioprocessing Excellence Awards 2021
SINGAPORE, June 25, 2021 /PRNewswire/ -- GenScript receives the "Best Contract
Development and Manufacturing Organization Award" on the Korea Bioprocessing
Excellence Awards 2021 held on 24th June 2021. GenScript achieve the Best CDMO
award for two years in a row.
2021-06-25 10:30
19418
Samsung Biologics Issues Its First Annual Sustainability Report
* Consolidation of the company's roadmap to creating an improved business environment * Establishment of an ESG Committee for its continued efforts for environmental performance * Showcases the company's long-term commitment to social responsibility as part of its mission to build a bett...
2021-06-25 09:01
23401
Moving ahead: Copan announces a major rebranding and launches a new website
BRESCIA, Italy, June 25, 2021 /PRNewswire/ -- Time of change for Copan. The Italian preanalytics company announced the completion of an extensive rebranding initiative which includes a new logo and a new website with updated functionalities. The rebranding aims to represent at best the company va...
2021-06-25 08:25
3831
Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Glucagon-like Peptide-1 and Glucagon Receptor Dual Agonist in Overweight or Obese Chinese Participants at the American Diabetes Association's 81st Scientific Sessions
SAN FRANCISCO and SUZHOU, China, June 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-06-25 08:00
7504
Bridge Biotherapeutics Integrates CDD Vault Collaborative Database Solution into Its R&D Platform to Harmonize Research and Drug Discovery Project Management
- Bridge has been enhancing its research and drug discovery engines by efficiently managing scientific assets on a collaborative database solution - CDD provides a secure research database platform enabling seamless collaboration between drug discovery and development teams that are in different...
2021-06-25 05:57
2769
Peijia Medical's Jasper® SS Detachable Coil Receives NMPA Approval for Commercialization
SUZHOU, China, June 24, 2021 /PRNewswire/ -- On June 15, 2021, Jasper® SS—a new detachable coil independently developed by Achieva Medical, subsidiary of Peijia Medical (9996.HK)—was approved by the National Medical Products Administration ("NMPA") for commercialization (registration number GXZZ ...
2021-06-25 00:27
17295
Triastek Closes US$ 50 Million Series B Financing, Co-led by Matrix Partners China and CPE
NANJING, China, June 24, 2021 /PRNewswire/ -- Triastek, Inc. (Triastek), a global leader in 3D printed pharmaceuticals, has completed its Series B financing, raisingUS$ 50 million (RMB 330 million). This round of investment was co-led by Matrix Partners China and CPE, with participation from S...
2021-06-25 00:26
4416
GenesisCare Expands their MR-guided Radiotherapy Reach with the Purchase of Multiple MRIdian® Systems
Master agreement includes program plans for up to a further 14 systems with immediate expansion in 2 key markets CLEVELAND, June 24, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that GenesisCare has entered into a master purchase agreement for up to 14 MRIdian® MR-Guided The...
2021-06-24 22:33
14830
Triastek Closes US$ 50 Million Series B Financing, Co-led by Matrix Partners China and CPE
NANJING, China, June 24, 2021 /PRNewswire/ -- Triastek, Inc. (Triastek), a global leader in 3D printed pharmaceuticals, has completed its Series B financing, raisingUS$ 50 million (RMB 330 million). This round of investment was co-led by Matrix Partners China and CPE, with participation from Shan...
2021-06-24 20:43
3443
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan
SHENZHEN, China, June 24, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Tucidinostat (also known as Chidamide, Epidaza ®, HBI-8000) monotherapy of relapsed or refractory (R/R) adult T-cell le...
2021-06-24 19:00
3957
Advanced Aesthetic Technologies, Inc. Announces the Treatment of the First Patient in a Pivotal Clinical Trial in China with their Algeness® VL (2.5% Agarose Gel) Filler for the Correction of Moderate to Severe Nasolabial Folds
This new clinical trial is being conducted through their partnership with Lanzhou Biotechnique Development Co., LTD (LanDev) and their parent company China National Biotec Group Co., LTD (CNBG) and will be used to seek marketing approval inChina BROOKLINE, Mass., June 24, 2021 /PRNewswire/ -- Ad...
2021-06-24 18:00
3212
Week's Top Stories
Most Reposted
Asia Pacific Travellers Seek Familiarity, Practicality, Flexibility Amid Shifting Global Dynamics: Visa Report
[Picked up by 326 media titles]
2026-06-16 10:00
Visa and Mintoak Join Forces to Bring Merchant SaaS Capabilities to Acquirers Across Asia Pacific
[Picked up by 313 media titles]
2026-06-17 11:00Affinidi and CardInfoLink Put the Missing Trust Layer for AI Agents into Production
[Picked up by 301 media titles]
2026-06-19 09:00
MediThinQ and Synovis Micro Companies Alliance, Inc. Announce Strategic Global Distribution Agreement to Redefine Microsurgery with the SHIYA 3D Visualization Platform
[Picked up by 300 media titles]
2026-06-18 22:01
NOVVA Group acquires 120 MWp Philippines solar project, anchoring its AI-era power platform in Southeast Asia
[Picked up by 300 media titles]
2026-06-19 11:12
Most Read
Asia Pacific Travellers Seek Familiarity, Practicality, Flexibility Amid Shifting Global Dynamics: Visa Report
2026-06-16 10:00
7519
All Eyes on Korea: CSOP KOSPI 200 ETF (3121.HK) to List on HKEX Tomorrow
2026-06-17 21:17
6056
